Regenxbio (RGNX) Cash & Equivalents (2014 - 2026)
Regenxbio (RGNX) reported Cash & Equivalents of $36.49 million for Q2 2026, down 54.1% from $79.56 million a year earlier but up 139.6% from the prior quarter.
Powered by 
Analysis
Regenxbio (RGNX) Cash & Equivalents (2014 - 2026) Analysis & Trends
At the end of FY2025, Regenxbio posted Cash & Equivalents of $34.47 million, down 40.1% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -36.7% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $57.53 million in FY2024 (+66.6%), $34.52 million in FY2023 (-64.4%), $96.95 million in FY2022 (-71.9%) and $345.21 million in FY2021 (+2.0%).
- Five-year quarterly Cash & Equivalents spans a low of $15.23 million in Q1 2026 and a high of $345.21 million in Q4 2021.
- Year over year, Cash & Equivalents has now declined in each of the last three quarters, with an average decline of 6.6% over the last eight quarters.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2021 (growth of 145.0%); the low point was Q1 2026 (a decline of 88.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $15.23 million (Q1 2026), $34.47 million (Q4 2025) and $58.8 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 1.82 Bn |
| 10 | Regenxbio | 508.48 Mn | -228.57 Mn | - | 95.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 95.80 Mn |
| Jun 30, 2026 | 36.49 Mn |
| Mar 31, 2026 | 15.23 Mn |
| Dec 31, 2025 | 34.47 Mn |
| Sep 30, 2025 | 58.80 Mn |
| Jun 30, 2025 | 79.56 Mn |
| Mar 31, 2025 | 130.10 Mn |
| Dec 31, 2024 | 57.53 Mn |
| Sep 30, 2024 | 56.62 Mn |
| Jun 30, 2024 | 57.77 Mn |
| Mar 31, 2024 | 112.98 Mn |
| Dec 31, 2023 | 34.52 Mn |
| Sep 30, 2023 | 53.05 Mn |
| Jun 30, 2023 | 68.60 Mn |
| Mar 31, 2023 | 70.09 Mn |
| Dec 31, 2022 | 96.95 Mn |
| Sep 30, 2022 | 118.54 Mn |
| Jun 30, 2022 | 121.37 Mn |
| Mar 31, 2022 | 191.87 Mn |
| Dec 31, 2021 | 345.21 Mn |
API Access
Regenxbio Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();